Although there is no direct comparison of the SGLT1/2i sotagliflozin to the SGLT2is, a meta-analysis of SGLT2is has failed to show a reduction of stroke and only a modest reduction in the incidence of MI [3]. This evidence concerns the gene SLC5A1 and Stroke.